

Publikationen:

- 1.) von Tirpitz C., Pischulti G., **Klaus J.**, et al: Pathologische Knochendichte bei chronisch-entzündlichen Darmerkrankungen - Prävalenz und Risikofaktoren. Z Gastroenterol 1999 Jan;37(1):5-12.
- 2.) von Tirpitz C., **Klaus J.**, et al: Increase of bone mineral density with sodium fluoride in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2000 Jan; 12(1):19-24
- 3.) Reinshagen M., **Klaus J.**, von Tirpitz C.; Osteoporose bei chronisch entzündlichen Darmerkrankungen. Der Kassenarzt 2001;41:34-38.
- 4.) **Klaus J.**, Brueckel J., Steinkamp M., et al; High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut 2002 Nov;51(5):654-658.
- 5.) von Tirpitz C., **Klaus J.**, Steinkamp M., et al; Therapy of Osteoporosis in Patients with Crohn's Disease: A Randomised Study Comparing Fluoride and Ibandronate. Aliment Pharmacol Ther 2003;17:807-816.
- 6.) von Tirpitz C., **Klaus J.**, Steinkamp M. et al; Quantitative Ultrasound of the Distal Phalanges and Dual Energy X-Ray Absorptiometry in Crohn's Disease Patients with Osteoporosis. J Gastroenterol 2003; 38:238-243.
- 7.) von Tirpitz C., Epp S., **Klaus J.**, et al; Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease. Eur J Gastroenterol Hepatol 2003;15:1165-1170.
- 8.) von Tirpitz C., Steder-Neukamm U., Glas U., Sander S., Ring C., **Klaus J.**, Reinshagen M.; Osteoporose bei chronisch entzündlichen Darmerkrankungen, Ergebniss einer Umfrage bei Mitgliedern der Deutschen Morbus Crohn und Colitis ulcerosa Vereinigung (DCCV). Z Gastroenterol 2003;41:1145-1150.
- 9.) Kreck S, **Klaus J**, Leidl R, von Tirpitz C, Konnopka A, Matschinger H, König HH. Cost Effectiveness of Ibandronate for the Prevention of Fractures in Inflammatory Bowel Disease-Related Osteoporosis. Pharmacoconomics 2008;26(4)311-328
- 10.) Bosch J, Thabut D, Albillos A, Carbonell N, Spicak J, Massard J, D'Amico G, Lebrec D, de Franchis R, Fabricius S, Cai Y, Bendtsen F; International Study Group on rFVIIa in UGI Hemorrhage. Collaborators: **Klaus J.** Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial. Hepatology. 2008 May;47(5):1604-14.

- 11.) **Klaus J.**, Reinshagen M., Adler G., Böhm B.O., von Tirpitz Ch.; Bones and Crohn's: Estradiol deficiency in men with Crohn's disease is not associated with reduced bone mineral density. *BMC Gastroenterology* 2008, 8:48 (23 Oktober 2008)
- 12.) Drews BH, Barth TF, Hänle MM, Akinli AS, Mason RA, Muche R, Thiel R, Pauls S, **Klaus J**, von Boyen G, Kratzer W. Comparison of sonographically measured bowel wall vascularity, histology, and disease activity in Crohn's disease. *Eur Radiol*. 2009 Jun;19(6):1379-86.
- 13.) **Klaus J**, Spaniol U, Adler G, Mason RA, Reinshagen M, von Tirpitz C. Small intestinal bacterial overgrowth mimicking acute flare as a pitfall in patients with Crohn's Disease. *BMC Gastroenterol*. 2009 Jul 30;9(1):61. [Epub ahead of print]
- 14.) Kunsch S, Neesse A, Huth J, Steinkamp M, **Klaus J**, Adler G, Gress TM, Ellenrieder V. Increased Duodeno-Gastro-Esophageal Reflux (DGGER) in symptomatic GERD patients with a history of cholecystectomy. *Z Gastroenterol*. 2009 Aug;47(8):744-8. Epub 2009 Aug 6.
- 15.) Kleger A, Bommer M, Kunze M, **Klaus J**, Leithaeuser F, Wegener M, Adler G, Dikopoulos N. Case Report: First Reported Case of Disease: Peliosis Hepatis as Cardinal Symptom of Hodgkin's Lymphoma. *Oncologist*. 2009 Nov;14(11):1088-94. Epub 2009 Nov 4.
- 16.) Kratzer W, Akinli AS, Bommer M, Arnold F, Eggink S, Imhof A, Mason RA, **Klaus J**, Schuler A, Boehm BO, Haenle MM. Prevalence and risk factors of focal sparing in hepatic steatosis. *Ultraschall Med*. 2010 Feb;31(1):37-42. Epub 2010 Feb 15.
- 17.) Volker Kaechele, Markus Moehler, Manfred P. Lutz, Goetz von Wichert, Miriam Eisele, **Jochen Klaus**, Peter R. Galle, Guido Adler, Thomas Seufferlein. A phase I/II study of oxaliplatin and paclitaxel in patients with non-resectable cancer of the oesophagus and adenocarcinoma of the gastro-oesophageal junction: a study of the Arbeitsgemeinschaft Internistische Onkologie. *Cancer Chemother Pharmacol*. 2010 May;66(1):191-5. Epub 2010 Mar 31
- 18.) **Jochen Klaus**, Max Reinshagen, Katharina Herdt, Christoph Schröter, Guido Adler, Georg BT von Boyen, Christian von Tirpitz. Bones and Crohn's: No benefit of adding sodium fluoride or ibandronate to calcium and vitamin D. *World J Gastroenterol* 2011 January 21; 17(3): 334-342
- 19.) **Klaus J**, Haenle MM, Schröter C, Adler G, von Boyen G, Reinshagen M, von

- Tirpitz C. A single dose dose of intravenous zoledronate prevents glucocorticoid therapy associated bone loss in acute flare of Crohn's disease, a randomized controlled study. Am J Gastroenterol. 2011 Apr;106(4):786-93. Epub 2011 Mar 8.
- 20.) **Klaus J**, Reinshagen M, Herdt K, Adler G, von Boyen GBT, von Tirpitz C. Intravenous Ibandronate or Sodium-Fluoride - a 3.5 Years Study on Bone Density and Fractures in Crohn's Disease Patients with Osteoporosis. J Gastrointestin Liver Dis, 2011 Jun;20(2):141-8.
- 21.) Albrecht DA, Schuler A, Kratzer W, Vogt JL, Hänle MM, Mason RA, Lorenz R, **Klaus J**. Early ultrasound – A way to more efficient use of limited resources by shortening the length of stay? Journal of Medical Ultrasound. J Med Ultrasonics, 2011, 'Online First', DOI 10.1007/s10396-011-0315-x
- 22.) Lohmann M, Haenle MM, **Klaus J**, Kratzer W. Aus- und Weiterbildungssituation in der Abdomensonographie an deutschen Universitätskliniken - Vergleich 1999-2009. Z Gastroenterol. 2011 Aug;49(8):971-6. Epub 2011 Aug 2
- 23.) **Jochen Klaus***, Jan Hendrik Niess*, Johannes Stephani, Carolin Pflüger, Nadine Degenkolb, Ulrike Spaniol, Benjamin Mayer, Georgia Lahr, Georg B. T. von Boyen. NOD2 Polymorphism Predicts Response to Treatment in Crohn's Disease; First Steps to a Personalized Therapy. Dig Dis Sci. 2012 Apr;57(4):879-86. Epub 2011 Dec 7.
- 24.) Stephani J, Wagner M, Breining T, **Klaus J**, Niess JH. Metabolic alkalosis, acute renal failure and epileptic seizures as unusual manifestation of an upside-down stomach. Case Rep Gastroenterol 2012 May;6(2):452-8.
- 25.) van der Ham S, Haenle MM, **Klaus J**, Oztürk S, Lorenz R, Kratzer W. Ultrasonographically guided biopsy procedures: current practice in hospitals with established departments of gastroenterology. Z Gastroenterol. 2012 Sep;(50)9:989-95
- 26.) Posovszky C, Pfalzer V, Lahr G, Niess JH, **Klaus J**, Mayer B, Debatin KM, von Boyen GB. Age-of-onset-dependent influence of NOD2 gene variants on disease behaviour and treatment in Crohn's disease. BMC Gastroenterol. 2013 May 2;13:77. doi: 10.1186/1471-230X-13-77.
- 27.) Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group Co-Worker **Klaus J**.

- Vedolizumab as Induction and Maintenance Therapy in Crohn's Disease. *N Engl J Med.* 2013 Aug 22;369(8):711-21. doi: 10.1056/NEJMoa1215739.
- 28.) G. D'Haens, S. Lee, D. Tarabar, E. LOUIS, M. Klopocka, D.I. Park, **J. Klaus**, X. Hébutterne, W. Reinisch, S. Schreiber, K.J. Gorelick, J. Cheng, M. Hassan-Zahraee, L. Brown, A. Ahmad, A. Banerjee, F. Cataldi, W. Sandborn Anti-MAdCAM-1 Antibody (PF-00547659) for Active Refractory Crohn's Disease: Results of the OPERA study. OP022 ECCO 2015, Barcelona.
- 29.) Freudenmann RW, Espe J, Lang D, **Klaus J**, Gahr M, Schönfeldt-Lecuona C. Psychiatric Emergencies in the Emergency Room of the Ulm University Hospital in 2000 and 2010. *Psychiatr Prax.* 2015 Jul 9. [Epub ahead of print]
- 30.) Zink F, Kratzer W, Schmidt S, Oeztuerk S, Mason RA, Porzner M, **Klaus J**, Haenle MM, Graeter T. Comparison of Two High-End Ultrasound Systems for Contrast-Enhanced Ultrasound Quantification of Mural Microvascularity in Crohn's Disease. *Ultraschall Med.* 2016 Feb;37(1):74-81. Epub 2015 Aug 7.
- 31.) Hohwieler M, Renz S, Liebau S, Lin Q, Lechel A, **Klaus J**, Perkhofer L, Zenke M, Seufferlein T, Illing A, Müller M, Kleger A. "Miniguts" from plucked human hair meet Crohn's disease. *Z Gastroenterol.* 2016 Aug;54(8):748-59. doi: 10.1055/s-0042-105520. Epub 2016 Jul 14.
- 32.) Schölmerich J, Fellermann K, Seibold FW, Rogler G, Langhorst J, Howaldt S, Novacek G, Petersen AM, Bachmann O, Matthes H, Hesselbarth N, Teich N, Wehkamp J, **Klaus J**, Ott C, Dilger K, Greinwald R, Mueller R; International TRUST-2 Study Group. A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn's disease. *J Crohns Colitis.* 2016 Oct 5. pii: jjw184.